Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study

Overview of attention for article published in Frontiers in Medicine, January 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (56th percentile)
Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter: 2 X users

Readers on

mendeley: 5 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 15,737 followers.

RT @DrMohamadShehab: Last paper of 2022! Data from kuwait. 40% of our pts with IBD are either obese or overweight! Pts on anti-TNF combo…

30 Dec 2022

Reply Repost Favourite

Last paper of 2022! Data from kuwait. 40% of our pts with IBD are either obese or overweight! Pts on anti-TNF combo (+IMM) or vedolizumab mono are more likely to be obese and overweight. @TBessissow @dr_f_alrashed @dr_ahmad_gastro @AAlaliMD https:/

30 Dec 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.